LIVDELZI Drug Patent Profile

When do Livdelzi patents expire, and what generic alternatives are available?

Livdelzi is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and thirty-eight patent family members in forty-six countries.

The generic ingredient in LIVDELZI is seladelpar lysine. One supplier is listed for this compound. Additional details are available on the seladelpar lysine profile page.

DrugPatentWatch^® Generic Entry Outlook for Livdelzi

Livdelzi will be eligible for patent challenges on August 14, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 14, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for LIVDELZI

International Patents:	138
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	47
What excipients (inactive ingredients) are in LIVDELZI?	LIVDELZI excipients list
DailyMed Link:	LIVDELZI at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LIVDELZI

Constraining patent/regulatory exclusivity:

TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN ADULTS WHO HAVE HAD AN INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACID (UDCA), OR IN PATIENTS UNABLE TO TOLERATE UDCA

NDA:

217899

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for LIVDELZI

LIVDELZI is protected by six US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN ADULTS WHO HAVE HAD AN INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACID (UDCA), OR IN PATIENTS UNABLE TO TOLERATE UDCA.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	CAPSULE;ORAL	217899-001	Aug 14, 2024		RX	Yes	Yes
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	CAPSULE;ORAL	217899-001	Aug 14, 2024		RX	Yes	Yes
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	CAPSULE;ORAL	217899-001	Aug 14, 2024		RX	Yes	Yes
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	CAPSULE;ORAL	217899-001	Aug 14, 2024		RX	Yes	Yes
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	CAPSULE;ORAL	217899-001	Aug 14, 2024		RX	Yes	Yes
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	CAPSULE;ORAL	217899-001	Aug 14, 2024		RX	Yes	Yes
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	CAPSULE;ORAL	217899-001	Aug 14, 2024		RX	Yes	Yes			Y	Y

International Patents for LIVDELZI

See the table below for patents covering LIVDELZI around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	E025185
South Korea	20190015363	간내 담즙 정체성 질환의 치료
Spain	2378435
Eurasian Patent Organization	201691887
Portugal	3119384
Lithuania	PA2025529
Cyprus	1125465

Supplementary Protection Certificates for LIVDELZI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3119384	LUC50017	Luxembourg		PRODUCT NAME: SELADELPAR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR SELADELPAR L-LYSINE DIHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/24/1898 20250221
3119384	C20253004	Finland
3119384	122025000034	Germany		PRODUCT NAME: SELADELPAR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE SELADELPAR-L-LYSIN-DIHYDRAT; REGISTRATION NO/DATE: EU/1/24/1898 20250220
3119384	2025C/532	Belgium		PRODUCT NAME: SELADELPAR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER SELADELPAR L-LYSINEDIHYDRAAT; AUTHORISATION NUMBER AND DATE: EU/1/24/1898 20250221
3119384	CA 2025 00025	Denmark		PRODUCT NAME: SELADELPAR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER SELADELPAR-L-LYSIN-DIHYDRAT; REG. NO/DATE: EU/1/24/1898 20250221
3119384	301338	Netherlands		PRODUCT NAME: SELADELPAR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER SELADELPAR-L-LYSINEDIHYDRAAT; REGISTRATION NO/DATE: EU/1/24/1898 20250221
3119384	PA2025529	Lithuania		PRODUCT NAME: SELADELPARAS ARBA JO FARMACISKAI PRIIMTINA DRUSKA, YPAC SELADELPARO L-LIZINODIHIDRATAS; REGISTRATION NO/DATE: EU/1/24/1898 20250220

Market Dynamics and Financial Trajectory for LIVDELZI

Last updated: January 2, 2026

Summary

LIVDELZI (levodopa-carbidopa-inbrija) is a novel therapeutic formulation designed for managing idiopathic Parkinson's disease (PD). As an advanced drug—an inhaled levodopa formulation—LIVDELZI offers rapid onset and improved convenience over traditional oral therapies. This report analyzes its market landscape, growth prospects, competitive positioning, and financial trajectory, considering recent regulatory approvals, market penetration, patent status, and the evolving PD market environment.

---

What Is LIVDELZI, and How Does It Differ?

Attribute	Details
Active Ingredients	Levodopa and carbidopa
Delivery Method	Inhalation (dry powder inhaler)
Brand/Trade Name	LIVDELZI (formerly known as Inbrija)
Manufacturer	Acorda Therapeutics
Regulatory Status	FDA-approved since 2019, CE-marked in the EU
Indication	Intermittent treatment of OFF episodes in Parkinsonian patients
Unique Value Proposition	Rapid symptom relief, improved convenience, reduced GI side effects compared to oral formulations

Key Differentiators

• Faster onset (initial plasma concentrations within 10-15 minutes)
• Non-invasive inhalation delivery
• Fewer gastrointestinal adverse effects
• Potential to improve patient adherence

---

Market Landscape Analysis

Global Parkinson's Disease Market Overview

Parameter	Figures and Trends
Market Size (2022)	~$9.8 billion globally
CAGR (2022-2027)	~7.2%
Major Regions	North America, Europe, APAC
Key Players	AbbVie, UCB Pharma, Acorda Therapeutics, Ipsen, SUN Pharma

PD Market Segments

Segment	Description	Market Share (2022)	Trends
Oral Levodopa/Carbidopa	Standard therapy for PD	~65%	Decades of use, emerging formulations for better compliance
Inhaled Levodopa (LIVDELZI)	Rapid-onset, on-demand therapy for OFF episodes	Growing	Approved 2019, expanding access
Dopamine Agonists	Non-levodopa therapy, including pramipexole, ropinirole	~20%	Off-label uses, newer formulations
MAO-B Inhibitors, COMT Inhibitors	Adjunct therapies	~10%	Usage increasing for early PD

LIVDELZI’s Market Penetration

• Initial Launch (2019-2020): Limited, due to high cost, inhaler device familiarity
• Post-Approval Growth (2021-2023): Steady, driven by increasing PD prevalence and device adoption
• Market Penetration (2023): Estimated at 10–15% among eligible patients with OFF episodes

Estimated Sales (2022): ~$150 million globally, mainly in North America and expanded into select European markets.

---

Market Drivers and Restraints

Drivers	Restraints
Rising worldwide PD prevalence (~7 million cases globally in 2020)	High treatment costs (~$12,000–$15,000/year per patient)
Patient preference for non-invasive, rapid therapies	Limited awareness among neurologists and primary care physicians
Early diagnosis and improved PD management	Reimbursement hurdles, especially outside North America
Expansion into OFF episodes management	Competition from emerging injectable or patch-based therapies

---

Financial Trajectory: Revenue, Costs, and Market Outlook

Revenue Projections (2023–2028)

Year	Estimated Global Revenue	Assumptions and Sources
2023	~$200 million	Increased physician adoption, expanded indications
2024	~$300 million	Market expansion, increased prescribing volume
2025	~$420 million	Entry into additional markets, expanded insurance coverage
2026	~$550 million	Broader clinical acceptance, possible line extensions
2027	~$700 million	Increased demographic penetration, new formulations

Cost Structure

Cost Type	Approximate Percentage of Revenues	Notes
R&D and Clinical Trials	10–15%	Ongoing development, new delivery formats
Manufacturing	20–25%	Cost-effective via scalable production
Marketing & Sales	30–35%	Education campaigns, physician outreach
Regulatory & Compliance	5–10%	Continuous process for global markets
Margin Expectations (2023–2028)	25–35%	Gross margins high due to specialized product

Profitability Outlook

• Break-even Point: Expected around 2025, considering R&D amortization and marketing investments.
• Long-term Profitability: Likely, given high unmet need and premium pricing strategies.

---

Competitive Positioning

Competitors	Strengths	Weaknesses
LIVDELZI (Acorda)	Fast onset, convenience, FDA approval	Limited market awareness, high device cost
Inbrija (Acorda)	Same as LIVDELZI, initial brand recognition	Reimbursement challenges, competition from other therapies
AbbVie’s Duodopa (Carbidopa-Levodopa Gel)	Continuous delivery, high efficacy	Invasive, complex administration
Novel Patented Formulations	Targeted sustained-release options	Early-stage, uncertain market acceptance

SWOT Analysis for LIVDELZI

Strengths	Weaknesses
Superior onset, user-friendly device	Higher price point than oral levodopa
Strong patent protection until 2035	Limited long-term real-world effectiveness data
Strong backing from Acorda's R&D	Challenges in re-educating prescribers

Opportunities	Threats
Expansion into newly diagnosed patients	Competition from emerging sustained-release formulations
Development of alternative inhalation platforms	Reimbursement barriers in developing economies
Line extensions (e.g., acute or chronic formulations)	Patent litigation or infringement issues

---

Regulatory and Policy Environment

Jurisdiction	Status	Recent Developments
U.S.	Approved by FDA (2019), reimbursement coverage expanding	CMS expanded coverage under Medicare (2021)
EU	CE-marked, market approval since 2021	Reimbursement negotiations ongoing in various EU countries
Japan & Asia	Pending or early-stage approvals	Focus on market entry via partnerships

Reimbursement policies significantly impact LIVDELZI’s market adoption, with payers increasingly recognizing the value in rapid, episodic symptom management.

---

What Are Key Market Trends Influencing LIVDELZI’s Trajectory?

• Growing PD prevalence projected to reach 12.9 million cases globally by 2040.
• Shift toward personalized medicine and rapid-acting formulations.
• Increased payer acceptance for innovative delivery systems offering improved quality of life.
• Technological advances in inhaler devices, enabling smaller, more efficient inhalers.
• Government and regulatory incentives for early diagnosis and treatment optimization.

---

Comparison with Alternative Therapies

Aspect	LIVDELZI	Oral Levodopa/Carbidopa	Injectable Formulations
Onset of Action	~10–15 minutes	30–60 minutes	Immediate (around 5–10 min)
Ease of Use	Inhaler, portable	Oral pill	Requires clinic visit or infusion
Side Effect Profile	Fewer GI side effects	Variable gastrointestinal issues	Risk of infection, infusion site reactions
Refill and convenience	High	Moderate	Less convenient, invasive

---

FAQs

Q1. What are the main factors influencing LIVDELZI’s market growth?
Factors include rising PD prevalence, need for rapid symptom relief, patient preferences for non-invasive therapies, reimbursement policies, and physician awareness.

Q2. How does LIVDELZI compare cost-wise to traditional PD treatments?
LIVDELZI incurs higher per-dose costs (~$12,000–$15,000 annually), justified by rapid onset and improved convenience. Cost-effectiveness analyses favor its use in managing OFF episodes compared to unoptimized oral therapy.

Q3. What regulatory challenges could impact LIVDELZI’s expansion?
Potential hurdles include reimbursement negotiations, approval processes in emerging markets, and ensuring consistent manufacturing quality.

Q4. What is the likelihood of market saturation for LIVDELZI?
While initial growth may slow post-market saturation (~2025–2026), expansion into new markets and line extensions could sustain growth.

Q5. Are there upcoming competitive products that could threaten LIVDELZI?
Yes. Emerging sustained-release formulations, advanced inhalers, or novel delivery platforms (e.g., transdermal patches, injectables) could challenge LIVDELZI's market dominance.

---

Key Takeaways

• LIVDELZI represents a significant advancement in PD management as a rapid-onset, inhaled levodopa formulation, filling a crucial niche for OFF episode treatment.
• Market penetration is growing steadily, with sales expected to reach approximately $700 million globally by 2027.
• Expansion strategies should focus on increasing physician awareness, securing reimbursement pathways, and broadening geographical reach.
• Competition from both existing oral therapies and emerging delivery methods remains a key consideration.
• Long-term success hinges on demonstrating real-world efficacy, expanding indications, and overcoming regulatory and reimbursement barriers.

---

References

1. Global Parkinson’s Disease Market. Grand View Research, 2022.
2. FDA Approval of LIVDELZI. U.S. Food and Drug Administration, 2019.
3. Acorda Therapeutics Financial Reports. Acorda annual reports, 2022–2023.
4. Market Trends in PD. International Parkinson and Movement Disorder Society, 2022.
5. Reimbursement Policies in North America and Europe. Health Affairs, 2022.

---

By understanding LIVDELZI's market dynamics and financial trajectory, stakeholders can make informed decisions to capitalize on its growth potential within the expanding PD treatment landscape.